噻吗洛尔(Timolol) - 药物靶点：β-adrenoceptors_在研适应症：高血压，眼部疾病，干眼综合征_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol、Timolol (INN)、Timolol anhydrous

+ [2]

靶点

β-adrenoceptors

作用机制

β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Betaliq, Inc.初创企业Thea Pharma, Inc.

Novaliq GmbH

非在研机构

Alcon Research Ltd.

最高研发阶段批准上市

首次获批日期

美国 (1995-03-31),

高血压

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C13H24N4O3S

InChIKeyBLJRIMJGRPQVNF-JTQLQIEISA-N

CAS号26839-75-8

关联

89

项与噻吗洛尔相关的临床试验

NCT06643416 / Recruiting临床3期IIT

Efficacy and Safety of Add-on Topical Timolol in the Management of Epidermal Growth Factor and Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase Inhibitor-induced Paronychia: a Prospective Randomized Open-labelled Trial

To assess the clinical efficacy of add-on topical timolol 0.5% eye drops to betamethasone valerate 0.1% for the treatment of EGFR-TKI and ALK-TKI induced paronychia.

开始日期2024-10-09

申办/合作机构

Queen Mary Hospital

IRCT20150825023753N23 / Recruiting临床3期IIT

Comparison of fractional co2 laser therapy alone and with its combination with topical timolol or topical insulin in the treatment of acne scar, A randomized controlled clinical trial

开始日期2023-12-31

申办/合作机构

Shiraz University of Medical Sciences

NCT06140186 / Recruiting临床3期IIT

Efficacy and Safety of add-on Topical Timolol in the Management of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-induced Paronychia: A Prospective Randomized Open-labelled Trial

This study would assess the clinical efficacy of add-on topical timolol 0.5% gel to betamethasone valerate 0.1% for the treatment of EGFR-TKI induced paronychia. Eligible patients, who develop paronychia (affecting fingernails, toenails or both), will be included in this study. They will be randomized in 1:1 ratio using computer-generated randomization list to receive either combination of topical timolol 0.5% gel and betamethasone valerate 0.1% lotion application twice daily or betamethasone valerate 0.1% lotion application twice daily. Patients in timolol combination treatment group will receive topical timolol 0.5% gel twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% lotion twice daily with occlsuion for 1 month. Patients in routine arm would receive the management according to routine clinical practice, including prescription of betamethasone valerate 0.1% lotion twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks , up to 12 weeks to see the effect.

开始日期2023-04-01

申办/合作机构

Queen Mary Hospital

100 项与噻吗洛尔相关的临床结果

登录后查看更多信息

100 项与噻吗洛尔相关的转化医学

登录后查看更多信息

100 项与噻吗洛尔相关的专利（医药）

登录后查看更多信息

4,320

项与噻吗洛尔相关的文献（医药）

2025-01-01·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Novel quantum dots-based assay for the determination of anti-hypertensive drugs minoxidil and timolol in different matrices

Article

作者: El Sharkasy, Mona E. ; Ahmed, Esraa S ; Bahgat, Eman A ; Belal, Fathalla ; Ahmed, Esraa S. ; Saleh, Hanaa ; El Sharkasy, Mona E ; Bahgat, Eman A.

The present work reports a sensitive, affordable, and ecologically friendly spectrofluorimetric method for the assessment of two antihypertensive medications, namely minoxidil and timolol. Blue-emitting sulfur and nitrogen co-doped carbon quantum dots (S,N-CQDs) were generated by exposing soluble starch and thiourea to a 15-minute microwave treatment. The so- prepared nanodots displayed fluorescence at 276/430 nm with a quantum yield of 22 %. Inspection of the so-prepared nano-sensor verified their doping with nitrogen and sulfur, and their size was in the range of 4.5-9.03 nm. The proposed method was found to be rectilinear in the range of 0.20-5.0 and 2.0-30.0 µg/mL, with LOQs of 0.16 and 0.82 µg/mL for minoxidil and timolol, respectively. The developed method was employed to assess the concentrations of minoxidil and timolol in their pharmaceutical formulations, with %recoveries varying between 99.00 % and 101.94 %, and low RSD values (less than 2 %). The high sensitivity of the developed method allowed its use for timolol measurement in artificial aqueous humor, with % recoveries between 97.60 %.and 101.57 %. The study further examined how each analyte interacted with the prepared dots, leading to a quenching of their fluorescence. Additionally, an interference study was utilized to evaluate the specificity of the proposed approach through determining analyte levels in the existence of common additives, co-formulated drugs, and co-administered drugs. The analytical eco-scale, GAPI and AGREE assessment techniques were utilized to confirm the suggested method greenness.

2024-12-01·Colloids and Surfaces B: Biointerfaces

Oxidized cellulose microneedle patch combined with vascular embolization and local delivery of timolol maleate for hemangiomas

Article

作者: Guo, Yiqun ; Li, Haibo ; Pang, Ningdong ; Liu, Lu ; Tan, Xiaoyun ; Niu, Chuanqiang ; Zhou, Zijun ; Jiang, Hua ; Liu, Lang ; Jiang, Yizhou

Hemangiomas are superficial tumors characterized by dense vascular structures that often affect the patient's aesthetic appearance due to the obvious red appearance on the skin. Current treatments, especially timolol maleate in the form of eye drops and hydrogels, suffer from low transdermal drug delivery rates, resulting in prolonged treatment time. To address this challenge, our study introduced a soluble microneedle patch with dextran as the main material to form microcatheters for sustained delivery of timolol maleate. In addition, we proposed a vascular embolization strategy to disrupt the blood supply in hemangiomas. Oxidized cellulose (C-cellulose) was selected for its excellent hemostatic properties. We incorporated C-cellulose into dextran microneedles to facilitate thrombosis in the vascular-rich areas of hemangiomas. The innovative microneedle patch we developed can penetrate the skin to a depth of 430 μm and dissolve rapidly within 3 minutes, ensuring direct drug delivery to the subcutaneous layer. Notably, the treated skin area regained its original appearance within two hours after treatment. In addition to excellent skin permeability and rapid dissolution, these patches significantly promoted apoptosis and inhibited cell migration in mouse hemangioendothelioma EOMA cells. Our results demonstrate that this approach not only achieves significant tumor inhibition in a mouse hemangioma model, but also represents a more effective, convenient, and non-invasive treatment option. Therefore, dextran/C-cellulose/timolol maleate microneedle patch (MNs/Timolol) has broad clinical application prospects in the treatment of hemangiomas, minimizing the risk of additional damage and improving treatment efficacy.

2024-12-01·Pharmacology Biochemistry and Behavior

Acute exercise performed during the late consolidation phase improves memory persistence by hippocampal protein synthesis and catecholamine modulation

Article

作者: de Souza, Anna Cecilia Perreto Vieira ; Lima, Karine Ramires ; Mello-Carpes, Pâmela Billig ; Gomes, Gabriela Cristiane Mendes ; Perretto, Anna Cecilia ; Rosa, Ana Carolina de Souza da ; Sigaran, Gabriela Jaques ; de Souza da Rosa, Ana Carolina

Memory persistence is a crucial aspect of long-term memory (LTM) and involves late consolidation processes that modulate memory stability over time. Acute physical exercise (PE) has emerged as a potential strategy to modulate memory consolidation and enhance memory persistence. While its effects have been extensively explored in the early consolidation phase, its impact on the late phase remains unexplored. In this study, we investigated the effects and mechanisms of an acute PE on the late consolidation window of novel object recognition (NOR) memory in rats. A 30-minute running session applied 11 h after NOR memory acquisition significantly increased memory persistence for at least 7 days. The inhibition of hippocampal protein synthesis immediately after acute PE using anisomycin (a ribosomal inhibitor) or rapamycin (an mTOR pathway inhibitor) impaired the effect of PE on memory persistence. Animals only presented memory 1 day after acquisition. The same effect was observed with the inhibition of beta-adrenergic receptors by timolol. Although there were no differences between the groups' comparison, blocking D1/D5 receptors after acute PE resulted in a lack of memory persistence in the dichotomous testing (remember/non-remember). Therefore, our exploration of the mechanisms underlying this enhancement revealed the involvement of protein synthesis and the requirement of beta-adrenergic and dopaminergic D1/D5 receptors in the dorsal hippocampus. These findings provide valuable insights into PE as a potential memory modulator, contributing to expanding our understanding of memory consolidation dynamics and acute PE effects.

39

项与噻吗洛尔相关的新闻（医药）

2024-11-14

·医药观澜

用于婴幼儿血管瘤，两款改良型新药拟纳入优先审评

11月12日，中国国家药监局药品审评中心（CDE）官网最新公示，两款马来酸噻吗洛尔凝胶因”符合儿童生理特征的儿童用药品新品种、剂型和规格”拟纳入优先审评，用于增殖期浅表性婴儿血管瘤的治疗。这两款产品分别来自上海奥全生物和北京梅尔森医药。根据文献报道，婴幼儿血管瘤是儿童早期常见的良性肿瘤，其中70%以上为浅表型，头面部为好发部位，其次是躯干和四肢。血管瘤通常在婴儿出生后几周出现，在3个月时达高峰。75%的血管瘤随着婴儿长大会逐渐缩小并消失，无需治疗。虽然是良性肿瘤，但可能会导致溃疡，气道阻塞、心血管风险等常见并发症。而且，由于发生位置的关系，某些婴儿血管瘤可能导致呼吸和视力等功能损害、甚至危及生命。噻吗洛尔属于非选择性β-肾上腺素受体阻滞剂，此前在临床上用于治疗眼压升高或开角型青光眼患者的眼压升高。为减少口服普萘洛尔带来的全身不良反应，外用马来酸噻吗洛尔近年来正在被越来越多地作为全身用药以及众多观察等待患者的替代选择。然而目前尚无治疗婴幼儿血管瘤的噻吗洛尔外用药物获批上市。上海奥全生物医药科技有限公司是一家以制剂改良型新药为主营业务，致力于创新药研发和产业化的生物医药公司。据奥全生物公开资料介绍，该公司研发的马来酸噻吗洛尔凝胶有效性及安全性已得到临床试验证实。北京梅尔森医药是一家专注于儿童药、罕见病用药及临床急需药物开发与生产的高新技术企业。该公司自2013年立项开发用于增殖期浅表性婴儿血管瘤治疗的专属局部外用制剂马来酸噻吗洛尔凝胶，并于2023年10月完成中国国内3期临床疗效观察试验，效果符合预期目标。参考资料：[1]中国国家药监局药品审评中心官网. Retrieved Nov 12, 2024, from https://www.cde.org.cn/main/xxgk/listpage/da6efd086c099b7fc949121166f0130c [2]上海奥全“马来酸噻吗洛尔凝胶”新药上市申请获NMPA受理. Retrieved Nov 1，2024, from https://mp.weixin.qq.com/s/J_uWaUFe_oYYlE-UEGKzIQ [3]郑家伟,王绪凯,江成鸿,等.外用马来酸噻吗洛尔治疗婴幼儿血管瘤中国专家共识[J].上海口腔医学, 2016. [4]科技创新看大兴——全球首创浅表性婴儿血管瘤外用治疗药物研发取得重要进展. Retrieved Oct 26，2023, from https://mp.weixin.qq.com/s/Z0CtynW2EqPOSTTFf4WmIA 内容来源于网络，如有侵权，请联系删除。

优先审批申请上市

2024-11-03

·医药观澜

用于婴幼儿血管瘤，改良型新药申报上市！奥全生物申报

▎药明康德内容团队编辑奥全生物近日宣布，该公司申报的马来酸噻吗洛尔凝胶上市申请已经获得中国国家药监局药品审评中心（CDE）受理。该产品本次申报上市的适应症为用于治疗增生期浅表型婴幼儿血管瘤。根据文献报道，婴幼儿血管瘤是儿童早期常见的良性肿瘤，头面部为好发部位，其次是躯干和四肢。血管瘤通常在婴儿出生后几周出现，在3个月时达高峰。75%的血管瘤随着婴儿长大会逐渐缩小并消失，无需治疗。虽然是良性肿瘤，但可能会导致溃疡，气道阻塞、心血管风险等常见并发症。而且，由于发生位置的关系，某些婴儿血管瘤可能导致呼吸和视力等功能损害、甚至危及生命。噻吗洛尔属于非选择性β-肾上腺素受体阻滞剂，此前在临床上用于治疗眼压升高或开角型青光眼患者的眼压升高。为减少口服普萘洛尔带来的全身不良反应，外用马来酸噻吗洛尔近年来正在被越来越多地作为全身用药以及众多观察等待患者的替代选择。然而目前尚无治疗婴幼儿血管瘤的噻吗洛尔外用药物获批上市。据奥全生物新闻稿介绍，该公司研发的马来酸噻吗洛尔凝胶有效性及安全性已得到临床试验证实。该产品上市后，有望为血管瘤婴幼儿患者提供一个安全、有效、使用及携带方便的治疗专用药物。上海奥全生物医药科技有限公司是一家以制剂改良型新药为主营业务，致力于创新药研发和产业化的生物医药公司。该公司围绕患者的临床需求对药物进行针对性改良，探索新的治疗方法，包括新剂型、新适应症和新给药方案。参考资料：[1]上海奥全“马来酸噻吗洛尔凝胶”新药上市申请获NMPA受理. Retrieved Nov 1，2024, from https://mp.weixin.qq.com/s/J_uWaUFe_oYYlE-UEGKzIQ [2]郑家伟,王绪凯,江成鸿,等.外用马来酸噻吗洛尔治疗婴幼儿血管瘤中国专家共识[J].上海口腔医学, 2016. 本文来由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈。转发授权及其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

上市批准

2024-10-31

·PRNewswire

Formosa Pharmaceuticals and DÁVI Farmacêutica Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain

TAIPEI, Oct. 31, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with DÁVI Farmacêutica ("DÁVI") in Portugal, for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a marketed innovative medicine for the treatment of inflammation and pain following ocular surgery. DÁVI is a trusted partner of Pharmathen Global Holding B.v., AZAD Pharma AG, NTC S.r.l. and Pfizer through marketing and promotion of Xalacom© (Latanoprost + Timolol) and Xalatan© (Latanoprost) for more than 12 years. DÁVI is one of the key players in the Portuguese Market, with over 100 years' history in the distribution and promotion of branded ophthalmology products. Clobetasol propionate ophthalmic suspension, 0.05% (APP13007), approved by the U.S. Food and Drug Administration (FDA) in March, 2024, was recently launched in the United States in September, 2024. The DÁVI licensing agreement includes upfront, commercialization milestones, and sales milestones, with additional considerations throughout the term of the agreement. APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT® nanoparticle formulation platform. The novel formulation enables a convenient and straightforward dosing regimen (twice daily for 14 days) while providing rapid and sustained relief of inflammation and pain. In a recent survey of 100 ophthalmic surgeons, rapid resolution of pain (~80% pain-free four days post-surgery) and low incidence of adverse events (<2%) were highlighted as key drivers to prescribing APP13007. APP13007 anticipates significant potential in Portugal, which has around 90,000 cataract surgeries, annually, as reported by Eurostat. "This partnership with DÁVI Farmacêutica, marks our first entry into a competitive EU market, opening the door for growth into other EU territories. DÁVI's experience and commitment to novel ophthalmic therapies is steadily apparent and Formosa Pharma appreciates their recognition of APP13007 as a worthy offering to patients recovering from ocular surgery." said Erick Co, President and CEO of Formosa Pharmaceuticals. Rui Alves, Business Development Manager of DÁVI Farmacêutica, stated, "We are excited at DÁVI to be partnering with Formosa and have the opportunity to offer this cutting-edge drug and technology to our ophthalmologists and patients, reinforcing our strong position in the market and the commitment to enhance the well-being of our people." About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which APP13007 was developed, improves the dissolution and bioavailability of APIs for topical, oral, and inhaler administration. Resulting formulations have high uniformity, purity, and stability, thereby allowing the utilization of poorly soluble or extremely potent drug agents which otherwise may face insurmountable challenges in safety, delivery, and penetration to target tissues. For more details about Formosa Pharma and APNT®, visit . About DÁVI Farmacêutica DÁVI Farmacêutica, is a century-old company and one of the key players in ophthalmology and ENT segments in Portugal. The company's core activities are the distribution & promotion of branded medicines with significant partnerships with major multinational pharmaceutical companies. Our daily mission is to give our patients the best option available in the market, making their lives better. To know more about DÁVI Farmacêutica, visit . SOURCE Formosa Pharmaceuticals Inc., WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

引进/卖出上市批准

100 项与噻吗洛尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08600	噻吗洛尔	S01ED01 C07AA06	DB00373

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
高血压	美国	Thea Pharma, Inc.	1995-03-31

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
眼部疾病	临床2期	美国	Betaliq, Inc.初创企业	2022-01-30
干眼综合征	临床2期	-	Novaliq GmbH	-
青光眼	药物发现	美国	Alcon Research Ltd.	2003-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02822729 (RENGE, Pubmed \| Jpn J Ophthalmol)	临床3期	高眼压症 \| 开角型青光眼	125	Omidenepag isopropyl 0.002%	夢遞襯鬱鏇醖構範齋範(鏇艱築襯範窪獵艱顧醖) = incidence: monotherapy [Groups 1 and 2], 18.8%; concomitant [Group 3], 45.0% 鑰網鏇鏇淵顧壓餘觸膚 (築鹽鹹蓋艱鹽顧築築範 ) 更多	-	2021-09-08
				Omidenepag isopropyl 0.002% + Timolol 0.5%
APAO2021	N/A	-	-	Topical Timolol Gel 0.5%	齋齋廠遞窪窪鹽窪鹽淵(壓憲鏇醖顧蓋夢糧壓範) = There were no obvious systemic or ocular side effects. 範顧糧廠選顧遞糧築壓 (鑰窪繭憲鏇願廠膚憲齋 ) 更多	-	2021-09-05
EDEN consortium (ARVO2021)	N/A	-	106	Latanoprost	(顧構夢齋願壓醖壓淵繭) = 網壓餘衊遞醖獵簾襯淵餘觸製憲夢襯鬱願顧膚 (淵艱餘窪糧蓋顧憲襯淵 )	不佳	2021-06-01
				Timolol	(顧構夢齋願壓醖壓淵繭) = 鹹鬱簾齋膚構積鹹網鏇餘觸製憲夢襯鬱願顧膚 (淵艱餘窪糧蓋顧憲襯淵 )
NCT03836664 (CTgov)	临床2期	偏头痛	25	Timolol (All Participants Post Timolol)	糧膚鬱觸顧鏇鬱醖範淵(淵鏇積觸窪鹹餘鹽醖構) = 願壓獵憲鏇構鑰鏇獵製觸觸鬱製鹹膚鬱顧製鏇 (鏇膚範衊襯餘蓋觸蓋選, 齋鑰顧顧餘夢鑰鹹鬱願 ~ 膚鏇餘壓選壓築糧構選) 更多	-	2019-07-02
				placebo+Timolol (All Participants Post Placebo)	糧膚鬱觸顧鏇鬱醖範淵(淵鏇積觸窪鹹餘鹽醖構) = 築積衊廠鏇醖遞選遞顧觸觸鬱製鹹膚鬱顧製鏇 (鏇膚範衊襯餘蓋觸蓋選, 簾餘鏇壓鏇鏇夢鑰遞獵 ~ 觸鑰遞淵窪壓顧製艱糧) 更多
NCT01677507 (ARVO2019)	临床4期	-	121	Timolol 0.5%	餘構糧醖襯窪衊壓醖淵(築衊壓願憲製憲餘廠獵) = 選鬱醖鏇衊製遞淵壓衊網築築鏇襯餘範膚襯淵 (顧衊願顧淵廠構淵膚蓋, 7.9)	积极	2019-07-01
				Latanoprost 0.005%	餘構糧醖襯窪衊壓醖淵(築衊壓願憲製憲餘廠獵) = 簾顧夢觸鑰鬱蓋顧鬱壓網築築鏇襯餘範膚襯淵 (顧衊願顧淵廠構淵膚蓋, 7.9)
NCT02630719 (CTgov)	N/A	偏头痛	10	Timolol eye drops (Timolol Eye Drops)	淵製壓積獵鬱餘夢獵蓋(糧遞顧鹽鑰鏇範簾顧簾) = 憲鏇鹽製鹽觸製顧餘遞鹹鹽壓構窪廠繭積廠窪 (顧齋簾衊構衊鬱範觸鏇, 艱糧鹽餘顧窪鏇構廠範 ~ 簾簾艱餘餘鑰夢蓋鏇積) 更多	-	2019-05-15
				Artificial tears (Artificial Tears)	淵製壓積獵鬱餘夢獵蓋(糧遞顧鹽鑰鏇範簾顧簾) = 簾蓋鬱獵廠鹹遞齋衊遞鹹鹽壓構窪廠繭積廠窪 (顧齋簾衊構衊鬱範觸鏇, 廠鑰齋廠鏇構窪獵製築 ~ 鏇衊鬱夢夢製積範築遞) 更多
NCT02742649 (CTgov)	临床1/2期	开角型青光眼	55	Fixed Combination+Timolol 0.5% (Fixed Combination (FC) Ocular Insert)	選鏇蓋衊憲鑰齋壓齋醖(範積淵範範糧鏇築糧範) = 繭獵廠獵鹽餘艱齋鑰廠糧齋淵觸廠衊鹽獵淵襯 (夢鏇繭餘鑰構鹹網範範, 齋觸觸壓選遞襯憲範窪 ~ 網繭壓築構製夢淵襯壓) 更多	-	2018-12-31
				Placebo Segment+Timolol 0.5%+Bimatoprost (Bimatoprost Ocular Insert)	選鏇蓋衊憲鑰齋壓齋醖(範積淵範範糧鏇築糧範) = 鑰鑰顧夢繭鏇鑰願夢醖糧齋淵觸廠衊鹽獵淵襯 (夢鏇繭餘鑰構鹹網範範, 襯鑰夢衊鬱網憲選選構 ~ 鏇鹹鹽顧憲壓選醖膚願) 更多
NCT01147601 (CTgov)	早期临床1期	毛细血管瘤	6	topical 0.5% Timolol (Topical 0.5% Timolol)	積鬱衊獵願壓網鑰網選(鑰壓餘築廠積衊積願築) = 襯鹹網選鏇餘淵鑰壓繭製鹽齋築壓糧鑰鏇築鬱 (鹹膚膚簾鑰鬱願鏇構窪, 齋遞襯鑰簾築願窪簾廠 ~ 遞顧憲範壓襯糧艱範獵) 更多	-	2017-07-05
				Control (placebo) group (Placebo)	積鬱衊獵願壓網鑰網選(鑰壓餘築廠積衊積願築) = 鹽醖願憲繭鏇膚範選築製鹽齋築壓糧鑰鏇築鬱 (鹹膚膚簾鑰鬱願鏇構窪, 淵製壓願積鹽餘醖獵廠 ~ 顧簾簾衊蓋構鹹繭構鑰) 更多
NCT02097719 (CTgov)	临床4期	青光眼	100	hypromellose 0.3%+bimatoprost 0.01% (Bimatoprost 0.01% and Hypromellose 0.3%)	願積範壓憲糧衊淵鹽製(夢獵願遞廠鑰膚壓壓廠) = 範鬱艱膚願築顧醖憲範獵壓範願淵淵鏇製襯簾 (醖積淵築鏇鑰夢製遞選, 製膚鹽觸鬱鹹壓醖醖繭 ~ 遞衊餘窪構淵鹽蓋蓋艱) 更多	-	2016-01-14
				timolol 0.5%+travoprost 0.004% (Travoprost 0.004% and Timolol 0.5%)	願積範壓憲糧衊淵鹽製(夢獵願遞廠鑰膚壓壓廠) = 鏇窪鏇齋築餘鑰願繭遞獵壓範願淵淵鏇製襯簾 (醖積淵築鏇鑰夢製遞選, 遞繭糧遞衊艱窪糧觸憲 ~ 築醖齋膚鏇艱積網構糧) 更多